Pharma Giants Bet on Revolutionary Cholesterol Form for Next Heart Drug Blockbusters
Novartis, Amgen, and Eli Lilly target lipoprotein(a) in race to develop next generation of cardiovascular treatments.
Read the full reporting at CNBC Markets.
Originally reported by CNBC Markets.